Tiffany Sin Hui Bong

Tiffany Sin Hui Bong

Auto-generated profile, based on publicly available information

Tiffany Sin Hui Bong

Colorectal Service, Department of General Surgery Sengkang General Hospital Singapore, 544886, 10 Sengkang East Way Singapore

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 January 2022 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
TBTiffany Sin Hui Bong
Tiffany Sin Hui Bong
JTJun Kiat Thaddaeus Tan
Jun Kiat Thaddaeus Tan
JHJuliana Teng Swan Ho
Juliana Teng Swan Ho
PTPuay Hoon Tan
Puay Hoon Tan
WLWing Sze Lau
Wing Sze Lau
YSYirong Sim
Yirong Sim
Bong TS, et al. J Breast Cancer. 2022 Feb;25(1):37-48. https://doi.org/10.4048/jbc.2022.25.e7

11 March 2022 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
TBTiffany S. H. Bong
Tiffany S. H. Bong
DADarius K. L. Aw
Darius K. L. Aw
SCShin Chuen Cheng
Shin Chuen Cheng
ECEdward Choke
Edward Choke
JTJia Sheng Tay
Jia Sheng Tay
Purpose: This study aims to describe an efficacious method using Cleaner XT rotational thrombectomy with catheter-directed thrombolysis and drug-eluting balloon angioplasty for the salvage of thrombosed arteriovenous fistulae and grafts. Materials and Methods: Retrospective analysis of all patients with thrombosed hemodialysis accesses who underwent endovascular salvage using the Cleaner XT rotational thrombectomy system at a single institution between June 2019 and September 2020 was performed. Patency was presented as Kaplan-Meier survival curves, and regression analysis was performed to examine predictors of postintervention primary patency and assisted primary patency based on Cox proportional-hazards model. Results: Thirty-four patients with thrombosed accesses underwent Cleaner XT rotational thrombectomy between June 2019 and September 2020. Technical and clinical success were both 100%. Mean procedure time was 62 ± 20 minutes. Mean postintervention primary patency time was 152 ± 51 days; 30, 90, 180, and 365 day postintervention primary patency rates were 89%, 80%, 68%, and 56%, respectively. Mean postintervention-assisted primary patency time was 157 ± 59 days; 30, 90, 180, and 365 day postintervention-assisted primary patency rates were 91%, 82%, 71%, and 59%, and 180 and 365 day secondary patency rates were 97.2% and 94.4%, respectively. Conclusion: The Cleaner XT rotational thrombectomy device demonstrates excellent clinical and technical success rates, with good patency results at all time points up to 12 months postintervention.

1 January 2022 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
TBTiffany Sh Bong
Tiffany Sh Bong
CYCharyl Jq Yap
Charyl Jq Yap
SSShereen Xy Soon
Shereen Xy Soon
TTTjun Yip Tang
Tjun Yip Tang
The aim of this case series was to document our early experience using combination therapy with UltraScore™ Focused Force percutaneous transluminal angioplasty balloon (BD Interventional, New Jersey, US) and Selution Sustained Limus Release (SLR)™ (M.A. MedAlliance SA, Nyon, Switzerland) sirolimus-coated balloon catheter for anti-restenotic drug elution, in the setting of multifocal high-grade stenosis for chronic limb threatening ischaemia. Our anecdotal experience was that preparing the lesion with scoring balloon and then using sirolimus drug-eluting balloon may have synergistic effect when used in tandem, especially in the setting of calcified arterial lesions, where the scoring wires may achieve deeper clefts within the atheromatous plaque to allow better drug absorption into the arterial wall. We report two cases with high-grade multifocal stenosis affecting the superficial femoral and anterior tibial arteries, respectively. Combination therapy using the scoring balloon to first prepare the lesion followed by sirolimus elution achieved technical and procedural success in both cases and a 100% 30-day primary patency. There were no complications related to flow-limiting dissections, vessel perforation or acute recoil. However, whether this combination therapy leads to better primary vessel patency with longer freedom from target lesion revascularization in the medium term remains to be determined.

21 May 2021 in Research Square
Verified
Preprint
Open access
PDF file
TBTiffany Sin Hui Bong
Tiffany Sin Hui Bong
TTThaddaeus Tan
Thaddaeus Tan
JHJuliana Ts Ho
Juliana Ts Ho
PTPuay Hoon Tan
Puay Hoon Tan
WLWing Sze Lau
Wing Sze Lau
YSYirong Sim
Yirong Sim
Purpose: Atypical ductal hyperplasia (ADH) is a high risk lesion with an increased risk of developing breast cancer. This study aims to identify factors predictive of malignant upgrade for ADH diagnosed on core needle biopsy (CNB) and to develop a nomogram to facilitate evidence-based decision making.Methods: Retrospective analysis of women with CNB diagnosed ADH at the National Cancer Centre Singapore between 2010 and 2015 was performed. Cox proportional hazards regression was used to identify independent clinical, radiological and histological factors associated with malignant upgrade. A nomogram was constructed and multivariable logistic regression coefficients were used to estimate the predicted probability of upgrade for each factor combination. Combinations with the lowest predicted probabilities (≤5%) were identified as low risk. Model sensitivity, specificity, positive and negative predictive values were assessed.Results: From 2010-2015, 238,122 women underwent screening under the national breast cancer screening programme. 29,564 women were recalled and 5742 CNBs were performed, of which 2686 were performed at NCCS. 88 patients (90 lesions) were diagnosed with ADH. 26 lesions were upgraded to a breast malignancy on excision biopsy. On univariate analysis, presence of a mass on either ultrasound (p= 0.018) or mammogram (p=0.026), presence of mammographic microcalcifications (p=0.047), diffuse microcalcification distribution (p=0.034), mammographic parenchymal density (p=0.008), presence of microcalcifications on biopsy (p=0.037) and three or more separate foci of ADH found on biopsy (p=0.024) were associated with malignant upgrade. Mammographic parenchymal density (Hazard ratio= 0.04, 95% CI 0.005-0.35, p=0.014), presence of a mass on ultrasound (Hazard ratio= 10.50, 95% CI 9.21-25.2, p=0.010) and number of foci of ADH (Hazard ratio = 1.877, 95% CI 1.831-1.920, p=0.002) remained significant on multivariate analysis and were included in the normogram which demonstrated good discrimination with C-statistic of 0.81 [95% CI, 0.74 to 0.88].Conclusion: Our model provides good discrimination of breast cancer risk prediction in patients with ADH on CNB. A subset of women at low risk (<5%) of upgrade to cancer may avoid surgical excision following a core-needle biopsy diagnosis of ADH.

17 May 2022 in Anz Journal of Surgery
Verified
Journal Article
Closed access
TBTiffany Sin Hui Bong
Tiffany Sin Hui Bong
FFFung Joon Foo
Fung Joon Foo
FKFrederick H Koh
Frederick H Koh